Cardiovascular Disease (CVD) Medicines Optimisation: The Limits of Standard Care

Cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality worldwide. Yet in many GP practices, patients identified as being at risk are still managed through a traditional “standard care” model — a system that is increasingly strained under modern healthcare demands.

How the Standard Care Model Works

In most primary care settings, CVD management follows a familiar pathway:

• Administrative teams manage patient call-and-recall systems for blood pressure reviews.
• Patients attend the practice for in-person checks, typically conducted by a nurse or healthcare assistant.
• When medication adjustments are needed, cases are escalated to a GP for further assessment and prescribing decisions.

While this model has served practices for many years, it was designed for a very different healthcare landscape — one with lower patient volumes, fewer chronic conditions, and less clinical complexity.

---

The Problem: Why Standard Care Is No Longer Enough

1. A Rapidly Growing CVD Population

An ageing population and improved survival rates mean that more patients are living longer with cardiovascular risk factors and established CVD. The result is a steadily increasing workload for primary care teams, with greater demand for regular reviews, monitoring, and medication optimisation.

2. Lack of a Systemised, Automated Review Process

Many practices still rely on manual processes for identifying patients due for review and tracking treatment outcomes. Without a structured, automated methodology for medicines optimisation:

• Reviews may be reactive rather than proactive
• Opportunities for earlier intervention can be missed
• Variation in care delivery increases

A fragmented approach makes it difficult to ensure every eligible patient receives timely, guideline-aligned optimisation.

3. Mounting Pressure on Primary Care

Primary care is under unprecedented strain. GP workloads continue to rise, clinician time is limited, and administrative capacity is stretched. When medication changes depend on GP review:

• Decision-making bottlenecks occur
• Treatment intensification may be delayed
• Preventative care can lose priority to acute demands

4. Increasing Guideline Complexity

Cardiovascular guidelines are continually evolving, with layered recommendations for blood pressure, lipid management, antiplatelet therapy, diabetes control, and kidney protection. Applying these consistently across large patient cohorts is challenging without robust decision-support systems.

5. Insufficient Clinical Decision Support

Without integrated tools that flag suboptimal therapy, contraindications, or missed optimisation opportunities, clinicians must rely heavily on manual review and memory — an approach that is both time-consuming and prone to variation.

---

The Impact on Patients

When medicines optimisation is inconsistent or delayed:

• Blood pressure may remain uncontrolled
• Lipid levels may not reach target
• Polypharmacy risks may increase
• The likelihood of preventable heart attacks and strokes remains higher than necessary

Standard care models often struggle to deliver the proactive, data-driven optimisation required to significantly reduce cardiovascular events at scale.

---

Moving Beyond Standard Care

To improve outcomes in today’s environment, CVD management requires:

• Structured, systemised review pathways
• Automated identification of patients needing optimisation
• Embedded decision support aligned with current guidelines
• Efficient delegation of tasks within the multidisciplinary team
• Reduced reliance on GP-only medication adjustments

Modernising medicines optimisation is no longer optional — it is essential to reduce preventable cardiovascular events while protecting already stretched primary care teams.

---

If you would like, I can also refine this article to position your organisation or service as the innovative solution to these challenges (for example, focusing on automation, pharmacist-led optimisation, or digital decision-support systems).